Entrada Therapeutics, which received early funding from CureDuchenne, has provided updates on the status of several exon skipping programs. We are pleased to share that they have dosed the first […]
CureDuchenne was an early investor in Dyne Therapeutics in 2020, and congratulates the company for receiving Breakthrough Therapy Designation from the US FDA for DYNE-251, their exon 51-skipping agent for the treatment of […]
CureDuchenne was an early investor in Avidity Biosciences in 2018, and congratulates the company for receiving Breakthrough Therapy Designation from the US FDA for delpacibart zotadirsen (abbreviated as del-zota), their exon 44-skipping agent […]
Capricor Therapeutics announced that it has received a Complete Response Letter indicating that the FDA has completed the review of Deramiocel for Duchenne cardiomyopathy, but would be unable to approve […]
